Walkers Asset Recovery

Fifteen Walkers lawyers were recognised in the 2017 Who's Who Legal Asset Recovery guide. This is more than any other global law firm worldwide.

Read More

'Band One'

Walkers has been ranked as a Band One 'Global-Wide' provider of offshore legal services in Chambers and Partners' 2017 Global Guide.

Read More


Following the recent result in the United Kingdom's EU referendum, Walkers has created a Brexit page dedicated to providing our clients relevant information about the jurisdictions in which we practice.

Read More

Dubai Award

Walkers (Dubai) has been awarded Best Offshore Law Firm 2017 at the MENA Fund Manager Fund Awards.

Read more

Walkers is a leading international law firm. We advise on the laws of Bermuda*, the British Virgin Islands, the Cayman Islands, Guernsey, Ireland and Jersey.

Legal Internships, Scholarships and Articles of Clerkship

Walkers is pleased to announce that it has opened the application process for its 2017 legal scholarships, internships and Articles of Clerkship programmes.


More Information

Browse Professionals
by last name

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Find a Professional
Search by one or more criteria

Andrew Miller enters Legal Week’s Private Client Global Elite 2017

Walkers partner Andrew Miller has been awarded a nomination in Legal Week’s Private Client Global Elite 2017. The list aims to highlight the premier trusts and private client lawyers around the world.

Private Client Global Elite 2017 received more than 4,000 submissions across nineteen jurisdictions, but only the top 5%, as identified by a peer-based advisory board and the ALM editorial board, were included on the list.

Walkers' wealth structuring group has substantial experience of working with high and ultra-high net worth individuals, their advisers, family offices and fiduciaries, as well as many of the leading financial institutions globally, on all aspects of international wealth structuring.

Whilst we specialise in British Virgin Islands, Cayman Islands, Guernsey and Jersey law, we take an holistic global approach in our advice to clients working with our unparalleled network of contacts throughout the world.

We fully understand the needs of wealthy internationally mobile families in ensuring the preservation of family wealth, including businesses, through the generations.

Cessation of Regulated Mutual Funds in 2017

With Q4 fast approaching, if managers and operators are considering winding up a Cayman Islands regulated mutual fund (a “Fund”), it would be prudent to start the process as soon as possible with a view to completing it by year-end and minimising and/or precluding 2018 annual fees.

Funds that are registered with the Cayman Islands Monetary Authority (“CIMA”) must submit a deregistration application and satisfy all deregistration requirements. Unless the Fund qualifies for an audit waiver (only granted in limited circumstances), this includes the filing of a "stub audit" up to the date a third party liquidator has been appointed or, if no third party liquidator has been appointed, to the date of final distribution or to the date that the final net asset value was calculated, with subsequent events notes to confirm that the final distribution has been paid to investors. Once the deregistration application is submitted, the Fund will be removed from active status and placed in Licence Under Termination (“LUT”) status with CIMA. During the first six months of LUT status, the operator is required to provide CIMA with comprehensive and ongoing updates as to the status and progress of the winding down. After this six month period, CIMA will contact the Fund to collect outstanding documents and/or fees and failure to provide them in a timely manner may result in CIMA taking administrative action to cancel the Fund's registration.

The stub audit requirement means that, in addition to filing the core deregistration requirements and supporting affidavit before 31 December, the Fund must file the stub audit with the accompanying Fund Annual Return (“FAR”) Form and pay to CIMA the FAR filing fee on or before 31 December in order to complete the deregistration application and avoid half-year CIMA fees being charged for 2018. Given the possible timing hurdles this may present for some funds, it is imperative that the Fund engages with its auditors and offshore counsel early in the wind down process to maximise regulatory and service provider cost savings for the Fund.

Following CIMA confirmation of deregistration, the Fund can focus on the administrative wind down process. If the wind down of a Fund is not completed before the end of January 2018, the Fund will be liable for annual government fees as well as ongoing service provider fees.

Consequently, once a considered assessment has been made to terminate a Fund, it is important that sufficient time and resources are allocated to complete the wind down process and minimise and/or preclude annual fees for the following year

Taylors Acts for SoftBank Vision Fund Investment in Roivant Sciences

Taylors (in association with Walkers) has acted as Bermuda counsel to SoftBank Vision Fund, which led a $1.1 billion equity investment in Roivant Sciences. The investment, which includes existing shareholder participation, is intended to accelerate the launch of new subsidiaries within and beyond the biopharma industry. The Taylors team, led by partner Jonathan Betts, worked alongside Cooley LLP, as lead US counsel. 

“Roivant has attracted world-class talent in its pursuit of developing and commercializing drugs that target large unmet medical needs,” said Akshay Naheta, managing director of SoftBank Group International, in a news release. “We are impressed with the ambition and track record of the Roivant team and look forward to supporting them in the next step of their journey, as they look to effectively harness technology and leverage big data across all aspects of their business.”

Roivant, which was founded in 2014, is dedicated to transformative innovation in healthcare. It focuses on realizing the full potential of promising biomedical research by developing and commercializing novel therapies across diverse therapeutic areas. It partners with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly developed and delivered to patients.

The SoftBank Vision Fund invests globally in the businesses and technologies that will enable the next stage of the Information Revolution, and make tomorrow’s world leading businesses possible. It invests across all technology sectors and geographies, including computational biology, data-driven healthcare and technology-enabled pharmaceutical businesses.